EBM --- Journal Reading Presenter :林禹君 Date : 2005/10/26.

Slides:



Advertisements
Similar presentations
Evidence-Based Medicine Critical Appraisal of Therapy Department of Medicine - Residency Training Program Tuesdays, 9:30 a.m. - 12:00 p.m., UW Health Sciences.
Advertisements

EVIDENCE BASED MEDICINE for Beginners
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2014.
Critical Appraisal of an Article on Therapy. Why critical appraisal? Why therapy?
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2009.
1.A 33 year old female patient admitted to the ICU with confirmed pulmonary embolism. It was noted that she had elevated serum troponin level. Does this.
Journal Club Alcohol and Health: Current Evidence January-February 2006.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Journal Club Alcohol and Health: Current Evidence September–October 2004.
Statistics for Health Care
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2009.
Critical Appraisal of an Article on Therapy (2). Formulate Clinical Question Patient/ population Intervention Comparison Outcome (s) Women with IBS Alosetron.
The Bahrain Branch of the UK Cochrane Centre In Collaboration with Reyada Training & Management Consultancy, Dubai-UAE Cochrane Collaboration and Systematic.
Are the results valid? Was the validity of the included studies appraised?
JAMA: Users’ guide to evidence-based medicine
DEB BYNUM, MD AUGUST 2010 Evidence Based Medicine: Review of the basics.
CAT 2: Therapy Maribeth Chitkara, MD Rachel Boykan, MD Stony Brook Long Island Children’s Hospital.
Academic Viva POWER and ERROR T R Wilson. Impact Factor Measure reflecting the average number of citations to recent articles published in that journal.
EVIDENCE BASED MEDICINE Effectiveness of therapy Ross Lawrenson.
How to Read Systematic Reviews : An Approach For The Clinician Part (1) Akbar Soltani. MD,MS, Endocrinologist Tehran University of Medical Sciences (TUMS)
A Systematic Review On The Hazards Of Aspirin Discontinuation Among Patients With Or At Risk For Coronary Artery Disease Giuseppe Biondi Zoccai Hemodynamics.
Critiquing for Evidence-based Practice: Therapy or Prevention M8120 Columbia University Suzanne Bakken, RN, DNSc.
How to Analyze Therapy in the Medical Literature (part 2)
Understanding real research 4. Randomised controlled trials.
EBM --- Journal Reading Presenter :顏志維 Date : 2005/10/17.
This material was developed by Oregon Health & Science University, funded by the Department of Health and Human Services, Office of the National Coordinator.
Landmark Trials: Recommendations for Interpretation and Presentation Julianna Burzynski, PharmD, BCOP, BCPS Heme/Onc Clinical Pharmacy Specialist 11/29/07.
Clinical Writing for Interventional Cardiologists.
ALI R. RAHIMI, BOBBY WRIGHTS, MD, HOSSEIN AKHONDI, MD & CHRISTIAN M. RICHARD, MSC Clinical Correlation Between Effective Anticoagulants & Risk of Stroke:
Vanderbilt Sports Medicine Chapter 5: Therapy, Part 2 Thomas F. Byars Evidence-Based Medicine How to Practice and Teach EBM.
Therapeutics: Finding a “Cure” Why Assess Therapy Articles? Evidence-based medicine Starting point for treatment decisions Apply evidence to your patients.
Wipanee Phupakdi, MD September 15, Overview  Define EBM  Learn steps in EBM process  Identify parts of a well-built clinical question  Discuss.
Evidence-Based Medicine – Definitions and Applications 1 Component 2 / Unit 5 Health IT Workforce Curriculum Version 1.0 /Fall 2010.
CAT 5: How to Read an Article about a Systematic Review Maribeth Chitkara, MD Rachel Boykan, MD.
A Simple Method for Evaluating the Clinical Literature “PP-ICONS” approach Based on Robert J. Flaherty - Family Practice Management – 5/2004.
EBM --- Journal Reading Presenter :呂宥達 Date : 2005/10/27.
This material was developed by Oregon Health & Science University, funded by the Department of Health and Human Services, Office of the National Coordinator.
EBM --- Journal Reading Presenter :傅斯誠 Date : 2005/10/26.
Compliance Original Study Design Randomised Surgical care Medical care.
EVALUATING u After retrieving the literature, you have to evaluate or critically appraise the evidence for its validity and applicability to your patient.
Vanderbilt Sports Medicine Evidence-Base Medicine How to Practice and Teach EBM Chapter 5 : Therapy.
/ 161 Saudi Diploma in Family Medicine Center of Post Graduate Studies in Family Medicine EBM Therapy Articles Dr. Zekeriya Aktürk
بسم الله الرحمن الرحیم.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
EBM --- Journal Reading Presenter :黃美琴 Date : 2005/10/27.
CRITICAL APPARAISAL OF A PAPER ON THERAPY 421 CORSE EVIDENCE BASED MEDICINE (EBM)
Critical Appraisal Course for Emergency Medicine Trainees Module 3 Evaluation of a therapy.
Article Title Resident Name, MD SVCH6/13/2016 Journal Club.
Critical Appraisal of a Paper Feedback. Critical Appraisal Full Reference –Authors (Surname & Abbreviations) –Year of publication –Full Title –Journal.
Critical Appraisal Course for Emergency Medicine Trainees Module 2 Statistics.
Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Choice of Antithrombotic Therapy for Stroke Prevention.
Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.
EBM R1張舜凱.
for Overall Prognosis Workshop Cochrane Colloquium, Seoul
Update on the Watchman Device CRT 2010 Washington, DC
The Importance of Adequately Powered Studies
Confidence Intervals and p-values
The Anglo Scandinavian Cardiac Outcomes Trial
Critical Reading of Clinical Study Results
مقدمه‌ای بر طب مبتنی بر شواهد
Dabigatran vs Warfarin in Patients with Atrial Fibrillation – Results
Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials  Giulia Renda, MD, PhD, Marta.
Interpreting Basic Statistics
EBM --- Journal Reading
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
EBM – therapy Dr. Tina Dewi J , dr., SpOG
Alcohol, Other Drugs, and Health: Current Evidence
Basic statistics.
Presentation transcript:

EBM --- Journal Reading Presenter :林禹君 Date : 2005/10/26

Users’ Guides to the Medical Literature Ⅱ. How to Use an Article About Therapy or Prevention B. What Were the Results and Will They Help Me in Caring for My Patients ? Gordon H. Guyatt, MD. MSc; David L. Sackett, MD. MSc; Deborah J. Cook, MD. MSc; for the Evidence-Based Medicine Working Group

Clinical scenario 65 y/o male Brief history –Controlled HTN –6 months arterial fibrillation, resistant to cardioversion –No evidence for valvular or coronary heart disease long-term anticoagulants: –Benefit (reduce embolic stroke) v.s risk (hemorrhage)

The PICO P: non valvular arterial fibrillation I: warfarin C: warfarin and control treatment O: risk of embolism and complications of anticoagulation

The Search GRATEFUL MED MeSH: –Arterial fibrillation, warfarin, Stroke(explode cerebrovascular disorders Limit –English language, randomized controlled trial 9 articles –3: editorials, commentaries –1: prognosis –1: quality of life  The most recent of the 4  Warfarin in the prevention of stroke associated with nonrheumatic arterial fibrillation, NEJM. 1992

What were the results ? How large was the treatment effect ? How precise was the estimate of the treatment effect ?

What were the results ? How large was the treatment effect? –Absolute risk reduction –Relative risk –Relative risk reduction(RRR) How precise was the estimate of treatment effect? –Point estimate –95% confidence interval: true 95% of the time

When is the sample size big enough? The larger the sample size, the greater of our confidence Positive study  lower boundary of the CI, still clinically significant? Negative study  upper boundary of the CI, be important Other criteria for CI

What can the clinician do if the CI around the RRR is not reported in the article P-value –0.05: lower bound of 95% CI for RRR= 0 Cannot exclude  treatment had no effect – 0 +/- standard error*2 Calculate CI yourself or someone else

Will the results help me in caring for my patients ? Can the results be applied to my patient care ? Were all clinically important outcomes considered ? Are the likely treatment benefits worth the potential harms and costs ?

Will the results help me in caring for my patients ? Can the results be applied to my patient care? –Inclusion/exclusion criteria –Whether there is some compelling reason why the results should “not” be applied to the p’t –Believable subgroup data: if difference is Large Very unlikely to occur by chance Results from analysis specified as a hypothesis before the study began One of only a very few subgroup analyses that were carried out Replicated in other studies

Were all clinically important outcomes considered? –Treatment improve outcomes that are “important” to patients –Substituted end point v.s important outcome Antiarrhythmic agent: abnormal ventricular depolarization  v.s life-threatening arrhythmia  –No deleterious effects on other outcomes Surgical trial  immediate and early mortality

Are the likely treatment benefits worth the potential harm and costs? –Number needed to treat (NNT)  before deciding on treatment, we must consider our patient’s risk of the adverse event if left untreated

Resolution of the scenario ( )

Conclusion Define the problem clearly Search: best available evidence Assess the quality of evidence Result Important Outcome Benefit/risk/cost

Thanks For Your Attention !!